LogicBio Therapeutics, Inc. is a genome editing company. The Company is focused on developing medicines to treat rare diseases in patients with unmet medical need. Its GeneRide technology platform is designed to integrate corrective genes into a patientâ€™s genome to provide a stable therapeutic effect. It focuses on targeting rare liver disorders in pediatric patients. Its discovery, research and development programs include various candidate, including LB-001, LB-101, LB 201 and LB-301. It is developing its lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia. LB-001 consists of a deoxyribonucleic acid construct including a gene encoding the human methylmalonyl CoA mutase (MUT) enzyme encapsulated in an AAV capsid. It is developing LB-101 for the treatment of Hemophilia B. LB-201 is being developed for the treatment of alpha-1-antitrypsin deficiency (A1ATD). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome animal disease models.